Kane Biotech Inc. (CVE:KNE – Get Free Report)’s share price hit a new 52-week low on Monday . The stock traded as low as C$0.03 and last traded at C$0.03, with a volume of 10000 shares changing hands. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The company has a market capitalization of C$6.15 million, a P/E ratio of -3.00 and a beta of 0.97. The business’s 50-day simple moving average is C$0.03 and its 200 day simple moving average is C$0.04. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Read More
- Five stocks we like better than Kane Biotech
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
